[Parkinsonism and use of selective serotonin uptake inhibitors].
Dietrichs
Espen
E
Nevrologisk avdeling Rikshospitalet 0027 Oslo. espen.dietrichs@klinmed.uio.no
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D004347:Drug Interactions; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D020734:Parkinsonian Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors